NTCVD: Development and Validation of new Diagnostic,
Preventive and Therapeutic Tools for the Prevention of
Cardiovascular Disease in Chronic Kidney Disease
COORDINATION: J. Jankowski (Charité) | CO-COORDINATION: T. Krahn (Bayer-Schering-Pharma)
PARTNER: V. Jankowski, K. Lehmann (Charite) | H. Bruck (Universitätsklinikum Essen) |
R. Herweg (MPI MolGen) | H. Lemke (EXcorLab)
PRINCIPAL INVESTIGATORS
2
4 1
3
6 7
5
1. Prof. Dr. Jankowski, Dr. Jankowski, Charité, Medizinische Klinik
IV, Berlin
2. Dr. Lehmann, PD Dr. Buschmann, Charité, Center for
Cardiovascular Research, Berlin
3. PD Dr. Herget-Rosenthal, Universitätsklinikum Essen, Klinik für Figure 2: General approaches of NTCVD
Nephrologie
4. Prof. Dr. Lehrach, Dr. Herwig, Max-Planck-Institut Berlin, Specific aims of NTCVD
Molecular Genetics
5. Dr. Lemke, EXcorLab GmbH, Obernburg Identify specific mediators, known and unknown, involved in
6. Dr. Krahn, Bayer Schering Pharma, Wuppertal .accelerated CVD in CKD
7. Associated Partner: Membrana GmbH, Wuppertal Identify among these mediators specific predictive biomarkers of
.accelerated CVD in CKD
Identify specifically new therapeutic targets to combat accelerated
.CVD in CKD
Integration into a web accessible CKD knowledgebase
Generate the scientific & technical basis for the development of
.both pharmaceutical therapies & extracorporeal removal strategies
Translate the results into new diagnostic, preventive and
.therapeutic tools and devices
CONCLUSION
This project aims to use proven and in some instances proprietary
Figure 1: Organization Chart of the Consortium molecular, genomic and proteomic approaches to identify and
■ SME ■ Clinic ■University ■
Research Institute ■
Industry
■ Molecular Phenotyping ■
Application Development –
Work Package
characterize the unknown mediators potentially involved in the
Partner – Work Package Leader →
Informational Flow accelerated CVD in CKD (stage 3-5). Furthermore the consortium will
have to characterize known mediators in detail with respect to their
SUMMARY
cardiovascular effects. The findings and results will culminate in the
The consortium will apply the novel tools “proteomics, peptidomics,
conception and development of innovative tools to diagnose, prevent and
metabonomics and genotyping”, which allow assessing the complete
treat CVD in CKD patients.
transcription and translation of the genomic capital to elucidate the genetic
and physiological background of CVD in CKD patients. This approach is Overall aims of NTCVD
focused on human samples i.e. tissues, cells and body fluids as humoral Prevention of CVD in CKD patients
targets are altered in CVD of CKD patients. Translate diagnostic biomarkers and preventive approaches to
.non-CKD population
NTCVD applies "forward genetics" from phenotype to gene to remedy the Remedy the causes of accelerated CVD in CKD
Identify and characterize biomarkers for cardiovascular risk in
causes of the enormously accelerated cardiovascular morbidity and death .CKD patients
in CKD (stage 3-5) and to develop novel diagnostics and therapeutics, Decrease therapy costs for CKD patients
Decrease overall costs, socio-economic challenges and number of
based on molecular genotyping and phenotyping. This will be done (A) .patients
by elucidating the role of recently identified mediators relating to CVD in Enhance German competitiveness in producing diagnostic and
.therapeutic tools
CKD by using bioassay approaches and pattern analysis of CKD patient
Correspondence: Prof. Dr. Joachim Jankowski, Charité, Med Klinik IV, Hindenburgdamm 30, 12200
samples, and (B) by the identification of yet unknown mediators. Berlin, Germany; Joachim.Jankowski@charite.de